HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla...
Digital Health Technologies for Charcot-Marie-Tooth (CMT) DiseasePatients attending the Clinical...
Join us for HNF 2024 CMT Clinical Trial Readiness Summit. To be held June 7&8th in San Diego, CA.
Do you want to make a difference in CMT research? HNF is looking for patients with a confirmed CMT diagnosis to participate in the CMT Biobank
In the fast-paced world of para triathlons, one name stands out among the rest: Skyler Fisher, a dynamic 19-year-old powerhouse representing Team USA.
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.
HNF Contributes CMTRN Data to C-Path’s RDCA-DAP, Strengthening Research Capabilities for Inherited...
Do you have late onset autosomal dominant CMT2 – subtype unknown, with breathing involvement, unexplained cardiac complications, and/or congenital cataracts?
Collaborative efforts between researchers, healthcare providers, and patients, facilitated by the Hereditary Neuropathy Foundation, has created a synergy that has accelerated the pace of discovery.
HNF is thrilled to announce that we have been accepted to host a 1-hour panel discussion during the Bio International Convention in San Diego, CA, in June 2024.
0 Comments